{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:42:43Z","timestamp":1793781763816,"version":"4.6.1"},"reference-count":91,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011404","name":"Indivior UK Limited","doi-asserted-by":"publisher","award":["KCLEXPOINDV19"],"award-info":[{"award-number":["KCLEXPOINDV19"]}],"id":[{"id":"10.13039\/100011404","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,10,30]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Opioid agonist, partial agonist and antagonist medications are used to treat opioid use disorder (OUD). This was the first omnibus narrative systematic review of the contemporary qualitative literature on patient experiences of receiving these medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Narrative systematic review using the sample, phenomenon of interest, design, evaluation and research framework.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data sources<\/jats:title><jats:p>PubMed, Embase and APA PsycINFO were searched between 1 January 2000 and 14 June 2023, with the addition of hand searches.<\/jats:p><\/jats:sec><jats:sec><jats:title>Eligibility criteria for selecting studies<\/jats:title><jats:p>Qualitative and mixed methods studies among adults with experience of receiving OUD treatment medication in community and criminal justice settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data extraction and synthesis<\/jats:title><jats:p>One reviewer conducted searches using the pre-registered strategy. Two independent reviewers screened studies and assessed quality using the Consolidation Criteria for Reporting Qualitative tool. Identified reports were first categorised using domains from the addiction dimensions for assessment and personalised treatment (an instrument developed to guide OUD treatment planning), then by narrative synthesis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From 1129 studies, 47 reports (published between 2005 and 2023) were included. Five major themes (and nine subthemes) were identified: (1) expectations about initiating treatment (barriers to access; motivations to receive medication); (2) responses to medication induction and stabilisation; (3) experience of the dispensing pharmacy (attending; medication dispensing); (4) experiences of maintenance treatment (services; dose adjustment; personal and social functioning); and (5) social factors (integration and stigma) and experiences of discontinuing treatment. Together these themes reflected and endorsed the importance of patient-centred care and clinically integrated services. Further qualitative research in real-world settings is needed on extended-release buprenorphine given the relative novelty of this medication option.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A narrative systematic review of the qualitative studies of medications for OUD endorsed the importance of patient-centred care and clinically integrated services.<\/jats:p><\/jats:sec><jats:sec><jats:title>PROSPERO registration number<\/jats:title><jats:p>CRD42019139365.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2024-088617","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T01:41:21Z","timestamp":1733362881000},"page":"e088617","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Patient experience of opioid use disorder treatment medications: a systematic review of contemporary qualitative research"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9137-5005","authenticated-orcid":false,"given":"Natalie","family":"Lowry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Najia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Mitcheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1307-2498","authenticated-orcid":false,"given":"John","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"2024120417411020000_14.12.e088617.1","unstructured":"Public Heath England . Part 1: introducing opioid substitution treatment (OST), 2021. Available: https:\/\/www.gov.uk\/government\/publications\/opioid-substitution-treatment-guide-for-keyworkers\/part-1-introducing-opioid-substitution-treatment-ost"},{"key":"2024120417411020000_14.12.e088617.2","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202201180"},{"key":"2024120417411020000_14.12.e088617.3","unstructured":"National Institute for Health and Care Excellence . Methadone and buprenorphine for the management of opioid dependence, 2007. Available: https:\/\/www.nice.org.uk\/guidance\/ta114"},{"key":"2024120417411020000_14.12.e088617.4","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06595-0","article-title":"Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone","volume":"23","author":"Marsden","year":"2022","journal-title":"Trials"},{"key":"2024120417411020000_14.12.e088617.5","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction"},{"key":"2024120417411020000_14.12.e088617.6","unstructured":"National Institute for Health and Care Excellence . Opioid dependence: buprenorphine prolongedrelease injection (buvidal) nice. 2019. Available: https:\/\/www.nice.org.uk\/advice\/es19\/chapter\/Key-messages"},{"key":"2024120417411020000_14.12.e088617.7","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-021-01764-9","article-title":"Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials","volume":"10","author":"Klimas","year":"2021","journal-title":"Syst Rev"},{"key":"2024120417411020000_14.12.e088617.8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"2024120417411020000_14.12.e088617.9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.23032","article-title":"Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail","volume":"4","author":"Lee","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2024120417411020000_14.12.e088617.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108764","article-title":"Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort","volume":"225","author":"Morgan","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2024120417411020000_14.12.e088617.11","article-title":"Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial","volume":"66","author":"Marsden","year":"2023","journal-title":"E Clin Med"},{"key":"2024120417411020000_14.12.e088617.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232086","article-title":"Retention of patients in opioid substitution treatment: A systematic review","volume":"15","author":"O\u2019Connor","year":"2020","journal-title":"PLoS One"},{"key":"2024120417411020000_14.12.e088617.13","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108651","article-title":"Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective","volume":"221","author":"Hall","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2024120417411020000_14.12.e088617.14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF02820690","article-title":"Quantitative vs qualitative research methods","volume":"67","author":"Lakshman","year":"2000","journal-title":"Indian J Pediatr"},{"key":"2024120417411020000_14.12.e088617.15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/dar.13421","article-title":"A qualitative meta-synthesis of pregnant women\u2019s experiences of accessing and receiving treatment for opioid use disorder","volume":"41","author":"Tsuda-McCaie","year":"2022","journal-title":"Drug Alcohol Rev"},{"key":"2024120417411020000_14.12.e088617.16","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1097\/JAN.0000000000000475","article-title":"The Lived Experience of Medication for Opioid Use Disorder: Qualitative Metasynthesis","volume":"34","author":"Techau","year":"2022","journal-title":"J Addict Nurs"},{"key":"2024120417411020000_14.12.e088617.17","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"2024120417411020000_14.12.e088617.18","unstructured":"Substance Abuse and Mental Health Services . Drug addiction treatment act of 2000. in: services. u.s. department of health & human services, editor. an act to amend the controlled substances act with respect to registration requirements for practitioners who dispense narcotic drugs in schedule iii, iv, or v for maintenance treatment or detoxification treatment. 2000. Available: https:\/\/www.govinfo.gov\/app\/details\/BILLS-106hr2634eh\/summary"},{"key":"2024120417411020000_14.12.e088617.19","unstructured":"McCormick MC . Subutex and Suboxone Approval Letter, (2002). U.S. Food and Drug Administration. 2002. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2002\/20732,20733ltr.pdf"},{"key":"2024120417411020000_14.12.e088617.20","unstructured":"Taylor R . Methadone and buprenorphine for the management of opioid dependence. in: national institute of health and care excellence, editor. west midlands. 2005. Available: https:\/\/www.nice.org.uk\/guidance\/ta114\/documents\/drug-misuse-methadone-and-buprenorphine-final-protocol2"},{"key":"2024120417411020000_14.12.e088617.21","doi-asserted-by":"publisher","DOI":"10.1177\/1049732312452938"},{"key":"2024120417411020000_14.12.e088617.22","unstructured":"The EndNote Team . EndNote. Philadelphia, PA: Clarivate Analytics, 2013."},{"key":"2024120417411020000_14.12.e088617.23","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"2024120417411020000_14.12.e088617.24","doi-asserted-by":"crossref","unstructured":"Braun V , Clarke V . How do you solve a problem like COREQ? A critique of consolidated criteria for reporting qualitative research. Elsevier, 2024.","DOI":"10.1016\/j.metip.2024.100155"},{"key":"2024120417411020000_14.12.e088617.25","unstructured":"Popay J . Guidance on the conduct of narrative synthesis in systematic reviews. A product from the ESRC methods programme Version. 2006;1:b92. doi:10.13140\/2.1.1018.4643"},{"key":"2024120417411020000_14.12.e088617.26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drugalcdep.2014.03.018","article-title":"Development of the Addiction Dimensions for Assessment and Personalised Treatment (ADAPT)","volume":"139","author":"Marsden","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"2024120417411020000_14.12.e088617.27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/jmwh.13165","article-title":"The Lived Experience of Postpartum Women Attending Outpatient Substance Treatment for Opioid or Heroin Use","volume":"66","author":"Proulx","year":"2021","journal-title":"J Midwife Womens Health"},{"key":"2024120417411020000_14.12.e088617.28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2019.105785","article-title":"Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system","volume":"128","author":"Rawson","year":"2019","journal-title":"Prev Med"},{"key":"2024120417411020000_14.12.e088617.29","first-page":"73","article-title":"Exploring Irish travellers\u2019 experiences of opioid agonist treatment: A phenomenological study","volume":"19","author":"Claffey","year":"2017","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"2024120417411020000_14.12.e088617.30","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/14659891.2020.1867661","article-title":"Risk perceptions and recovery threats for clients with a history of methadone maintenance therapy dropout","volume":"26","author":"Maina","year":"2021","journal-title":"J Subst Use"},{"key":"2024120417411020000_14.12.e088617.31","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.103092","article-title":"Pathways to \u201crecovery\u201d and social reintegration: The experiences of long-term clients of methadone maintenance treatment in an Irish drug treatment setting","volume":"90","author":"Mayock","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2024120417411020000_14.12.e088617.32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3109\/09687637.2014.987219","article-title":"Challenging biopower: \u201cLiquid cuffs\u201d and the \u201cJunkie\u201d habitus","volume":"22","author":"Gelpi-Acosta","year":"2015","journal-title":"Drugs Educ Prev Policy"},{"key":"2024120417411020000_14.12.e088617.33","article-title":"Untangling the Complexities of Substance Use Initiation and Recovery: Client Reflections on Opioid Use Prevention and Recovery From a Social-Ecological Perspective","volume":"15","author":"Maina","year":"2021","journal-title":"Subst Abuse"},{"key":"2024120417411020000_14.12.e088617.34","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1097\/ADM.0000000000000584","article-title":"Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment","volume":"14","author":"Randall-Kosich","year":"2020","journal-title":"J Addict Med"},{"key":"2024120417411020000_14.12.e088617.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108529","article-title":"Does incarceration influence patients\u2019 goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail","volume":"222","author":"Vail","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2024120417411020000_14.12.e088617.36","doi-asserted-by":"crossref","DOI":"10.1186\/s13011-018-0151-8","article-title":"Challenges in implementing opioid agonist therapy in Lebanon: a qualitative study from a user\u2019s perspective","volume":"13","author":"Ghaddar","year":"2018","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2024120417411020000_14.12.e088617.37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.socscimed.2015.04.008","article-title":"Negotiating structural vulnerability following regulatory changes to a provincial methadone program in Vancouver, Canada: A qualitative study","volume":"133","author":"McNeil","year":"2015","journal-title":"Soc Sci Med"},{"key":"2024120417411020000_14.12.e088617.38","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.drugpo.2013.04.004","article-title":"Substance, structure and stigma: parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods","volume":"24","author":"Chandler","year":"2013","journal-title":"Int J Drug Policy"},{"key":"2024120417411020000_14.12.e088617.39","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/dar.13616","article-title":"Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study","volume":"42","author":"Allen","year":"2023","journal-title":"Drug Alcohol Rev"},{"key":"2024120417411020000_14.12.e088617.40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13722-022-00288-4","article-title":"Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study","volume":"17","author":"Cheng","year":"2022","journal-title":"Addict Sci Clin Pract"},{"key":"2024120417411020000_14.12.e088617.41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.socscimed.2018.02.007","article-title":"The becoming of methadone in Kenya: How an intervention\u2019s implementation constitutes recovery potential","volume":"201","author":"Rhodes","year":"2018","journal-title":"Soc Sci Med"},{"key":"2024120417411020000_14.12.e088617.42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108667","article-title":"\u201cNot at all what I had expected\u201d: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study","volume":"136","author":"Brenna","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"2024120417411020000_14.12.e088617.43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/14659891.2010.526480","article-title":"Comparing methadone and Suboxone in applied treatment settings: the experiences of maintenance patients in Lanarkshire","volume":"16","author":"Tanner","year":"2011","journal-title":"J Subst Use"},{"key":"2024120417411020000_14.12.e088617.44","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/07347324.2018.1554982","article-title":"Psychological Needs of Women Treated with Methadone: Mixed Method Study","volume":"37","author":"Rahimi","year":"2019","journal-title":"Alcohol Treat Q"},{"key":"2024120417411020000_14.12.e088617.45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/SAR.S266838","article-title":"Patient-Reported Outcomes, Experiences and Satisfaction with Weekly and Monthly Injectable Prolonged-Release Buprenorphine","volume":"11","author":"Parsons","year":"2020","journal-title":"Subst Abuse Rehabil"},{"key":"2024120417411020000_14.12.e088617.46","doi-asserted-by":"crossref","DOI":"10.1186\/s13011-015-0031-4","article-title":"Opioid dependency rehabilitation with the opioid maintenance treatment programme - a qualitative study from the clients\u2019 perspective","volume":"10","author":"Granerud","year":"2015","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2024120417411020000_14.12.e088617.47","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-017-0189-3","article-title":"Barriers to retention in methadone maintenance therapy among people who inject drugs in Bangkok, Thailand: a mixed-methods study","volume":"14","author":"Hayashi","year":"2017","journal-title":"Harm Reduct J"},{"key":"2024120417411020000_14.12.e088617.48","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103788","article-title":"Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot","volume":"107","author":"Treloar","year":"2022","journal-title":"Int J Drug Policy"},{"key":"2024120417411020000_14.12.e088617.49","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/add.16171","article-title":"How do patients feel during the first 72\u2009h after initiating long-acting injectable buprenorphine? An embodied qualitative analysis","volume":"118","author":"Neale","year":"2023","journal-title":"Addiction"},{"key":"2024120417411020000_14.12.e088617.50","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/16066359.2019.1613522","article-title":"The effects of buprenorphine depot implants on patient sleep and quality of life: findings from a mixed-methods pilot trial","volume":"28","author":"Lynch","year":"2020","journal-title":"Addict Res Theory"},{"key":"2024120417411020000_14.12.e088617.51","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104002","article-title":"\u201cI just thought that was the best thing for me to do at this point\u201d: Exploring patient experiences with depot buprenorphine and their motivations to discontinue","volume":"115","author":"Clay","year":"2023","journal-title":"Int J Drug Policy"},{"key":"2024120417411020000_14.12.e088617.52","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042865","article-title":"How do people who use drugs experience treatment? A qualitative analysis of views about opioid substitution treatment in primary care (iCARE study)","volume":"11","author":"Alves","year":"2021","journal-title":"BMJ Open"},{"key":"2024120417411020000_14.12.e088617.53","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1017\/S079096670001209X","article-title":"Sharing control: user involvement in general practice based methadone maintenance","volume":"28","author":"O\u2019Reilly","year":"2011","journal-title":"Ir J Psychol Med"},{"key":"2024120417411020000_14.12.e088617.54","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/dar.12979","article-title":"The lived experience of Australian opioid replacement therapy recipients in a community-based program in regional Victoria","volume":"38","author":"Patil Vishwanath","year":"2019","journal-title":"Drug Alcohol Rev"},{"key":"2024120417411020000_14.12.e088617.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2011.03.009"},{"key":"2024120417411020000_14.12.e088617.56","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7517-10-24","article-title":"\u201cDiversion\u201d of methadone or buprenorphine: \u201charm\u201d versus \u201chelping.\u201d","volume":"10","author":"Havnes","year":"2013","journal-title":"Harm Reduct J"},{"key":"2024120417411020000_14.12.e088617.57","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108959","article-title":"Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients\u2019 experiences in Australia","volume":"227","author":"Barnett","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2024120417411020000_14.12.e088617.58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/00914509221140959","article-title":"The Social, Material, and Temporal Effects of Monthly Extended-Release Buprenorphine Depot Treatment for Opioid Dependence: An Australian Qualitative Study","volume":"50","author":"Lancaster","year":"2023","journal-title":"Contemp Drug Probl"},{"key":"2024120417411020000_14.12.e088617.59","doi-asserted-by":"crossref","first-page":"173","DOI":"10.17711\/SM.0185-3325.2019.023","article-title":"Psychosocial reintegration process in patients who receive maintenance treatment with methadone: A qualitative analysis","volume":"42","author":"Diaz-Negrete","year":"2019","journal-title":"Salud Ment"},{"key":"2024120417411020000_14.12.e088617.60","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2015.1088496"},{"key":"2024120417411020000_14.12.e088617.61","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1017\/S0790966700017171","article-title":"Methadone Treatment in Irish General Practice: Voices of Service Users","volume":"29","author":"Latham","year":"2012","journal-title":"Ir J Psychol Med"},{"key":"2024120417411020000_14.12.e088617.62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108119","article-title":"A mixed methods study exploring methadone treatment disclosure and perceptions of reproductive health care among women ages 18-44 years, Los Angeles, CA","volume":"118","author":"Bornstein","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"2024120417411020000_14.12.e088617.63","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.drugpo.2014.01.018","article-title":"Execution of control among \u201cnon-compliant\u201d, imprisoned individuals in opioid maintenance treatment","volume":"25","author":"Havnes","year":"2014","journal-title":"Int J Drug Policy"},{"key":"2024120417411020000_14.12.e088617.64","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/ADM.0b013e318297021e","article-title":"Meaning and methadone: patient perceptions of methadone dose and a model to promote adherence to maintenance treatment","volume":"7","author":"Sanders","year":"2013","journal-title":"J Addict Med"},{"key":"2024120417411020000_14.12.e088617.65","doi-asserted-by":"crossref","first-page":"572","DOI":"10.25122\/jml-2020-0038","article-title":"Reasons for Increasing Daily Methadone Maintenance Dosage among Deceptive Patients: A Qualitative Study","volume":"13","author":"Khosravi","year":"2020","journal-title":"J Med Life"},{"key":"2024120417411020000_14.12.e088617.66","doi-asserted-by":"crossref","DOI":"10.1111\/nin.12275","article-title":"Methadone maintenance treatment as social control: Analyzing patient experiences","volume":"26","author":"O\u2019Byrne","year":"2019","journal-title":"Nurs Inq"},{"key":"2024120417411020000_14.12.e088617.67","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-020-00413-z","article-title":"Retention and outcomes for clients attending a methadone clinic in a resource-constrained setting: a mixed methods prospective cohort study in Imphal, Northeast India","volume":"17","author":"Kermode","year":"2020","journal-title":"Harm Reduct J"},{"key":"2024120417411020000_14.12.e088617.68","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1108\/17449201111256907","article-title":"Subjective effects of prisoners using buprenorphine for detoxification","volume":"7","author":"Johnstone","year":"2011","journal-title":"Int J Prison Health"},{"key":"2024120417411020000_14.12.e088617.69","first-page":"5","article-title":"Study on users\u2019 perception of agonist opioid treatment in the galician network of drug addiction","volume":"18","author":"Carrera","year":"2016","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"2024120417411020000_14.12.e088617.70","article-title":"\u201cDon\u2019t Judge a Book Its Cover\u201d: A Qualitative Study of Methadone Patients\u2019 Experiences of Stigma","volume":"11","author":"Woo","year":"2017","journal-title":"Subst Abuse"},{"key":"2024120417411020000_14.12.e088617.71","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1080\/10826080500259497","article-title":"Users\u2019 experiences of heroin and methadone treatment","volume":"40","author":"Gourlay","year":"2005","journal-title":"Subst Use Misuse"},{"key":"2024120417411020000_14.12.e088617.72","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group . Drug misuse and dependence: UK guidelines on clinical management, Department of Health, London. 2017."},{"key":"2024120417411020000_14.12.e088617.73","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1409722"},{"key":"2024120417411020000_14.12.e088617.74","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2024120417411020000_14.12.e088617.75","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jsat.2019.06.007","article-title":"Opioid users\u2019 willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder","volume":"104","author":"Tompkins","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"2024120417411020000_14.12.e088617.76","doi-asserted-by":"crossref","first-page":"100161","DOI":"10.1016\/j.ssmqr.2022.100161","article-title":"Variation in intervention stigma among medications for opioid use disorder","volume":"2","author":"Madden","year":"2022","journal-title":"SSM - Qual Res Health"},{"key":"2024120417411020000_14.12.e088617.77","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069857","article-title":"Patients\u2019 perceptions of self-administered dosing to opioid agonist treatment and other changes during the COVID-19 pandemic: a qualitative study","volume":"13","author":"Scott","year":"2023","journal-title":"BMJ Open"},{"key":"2024120417411020000_14.12.e088617.78","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/acem.14814","article-title":"The limits of innovation: Directly addressing known challenges is necessary to improve the real-world experience of novel medications for opioid use disorder","volume":"30","author":"Morgan","year":"2023","journal-title":"Acad Emerg Med"},{"key":"2024120417411020000_14.12.e088617.79","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S2215-0366(19)30097-5","article-title":"Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial","volume":"6","author":"Marsden","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"2024120417411020000_14.12.e088617.80","article-title":"Facing addiction in America: The Surgeon General\u2019s Report on Alcohol, Drugs, and Health US Department of Health and Human Services, Office of the Surgeon General","volume":"37","author":"Day","year":"2016","journal-title":"Drug Alcohol Rev"},{"key":"2024120417411020000_14.12.e088617.81","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s11096-023-01557-1","article-title":"Provision of drug and alcohol services amidst COVID-19 pandemic: a qualitative evaluation on the experiences of service providers","volume":"45","author":"Richards-Jones","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"2024120417411020000_14.12.e088617.82","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.13.1689"},{"key":"2024120417411020000_14.12.e088617.83","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540460033029"},{"key":"2024120417411020000_14.12.e088617.84","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.annemergmed.2012.02.003","article-title":"Alcohol and drug use disorders among adults in emergency department settings in the United States","volume":"60","author":"Wu","year":"2012","journal-title":"Ann Emerg Med"},{"key":"2024120417411020000_14.12.e088617.85","doi-asserted-by":"publisher","DOI":"10.1006\/pmed.1997.0250"},{"key":"2024120417411020000_14.12.e088617.86","doi-asserted-by":"crossref","first-page":"37","DOI":"10.15585\/mmwr.mm6802a3","article-title":"Overdose Deaths Involving Fentanyl and Fentanyl Analogs - New York City, 2000-2017","volume":"68","author":"Colon-Berezin","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024120417411020000_14.12.e088617.87","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6533a2"},{"key":"2024120417411020000_14.12.e088617.88","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau1184","article-title":"Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016","volume":"361","author":"Jalal","year":"2018","journal-title":"Science"},{"key":"2024120417411020000_14.12.e088617.89","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"2024120417411020000_14.12.e088617.90","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s11606-021-06925-z","article-title":"\u201cI\u2019m a Survivor\u201d: Perceptions of Chronic Disease and Survivorship Among Individuals in Long-Term Remission from Opioid Use Disorder","volume":"37","author":"Pytell","year":"2022","journal-title":"J Gen Intern Med"},{"key":"2024120417411020000_14.12.e088617.91","doi-asserted-by":"publisher","DOI":"10.1080\/016396290931650"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-088617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T01:41:46Z","timestamp":1733362906000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-088617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":91,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,4]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bmjopen-2024-088617"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088617","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}